BioPlus-Interpex Korea opens with over 300 companies participating
Predicted impact: Low
Industry expo opening; routine event with no direct financial impact disclosed.
BioPlus바이오플러스
099430 · KOSDAQ · ₩099430 · 바이오플러스
₩3,320▲ ₩65 (2.00%)End-of-day · Oct 27, 2026 · End-of-day prices.
Price · 1Y −47.80%
- Market cap
- ₩205B
- Enterprise value
- ₩237B
- P/E
- 14.8×
- P/B
- 1.1×
- Dividend yield
- 2.1%
- ROE
- 7.8%
- Net margin
- 14.0%
Trailing 12 months from filed financial statements, as of H1 2026. Dividend yield: the 2025 dividend per share from the annual report ÷ today's price.
52-week range−49.7% from the high
₩3,065Today: ₩3,230 – ₩3,405₩6,600
Returns
- 1W−8.0%
- 1M+1.1%
- 3M−5.5%
- 6M−42.6%
- YTD−34.0%
- 1Y−47.8%
- Volume today
- 131,006
- 0.8× the 20-day average
- Traded today
- ₩434M
- Listed shares
- 61,640,722
- EPS (12 months)
- ₩225
- Earnings yield 6.8%
AI researchResearch being writtenOur AI is writing a report on this company from filed data, prices and news. Check back soon.
Upcoming dates
Full calendar →🎁 Gift this stock
Send a friend ₩100,000 of paper money in this stock. They get it when they join.
Signals
Quiet- BuzzQuietBuzz 44 of 100 (50 is a normal day for this stock).
- SentimentPositiveNews: Both reports describe a large, positive industry event with no negative news. Community: 0 bullish, 0 bearish posts this week.
- MomentumFlat0.5% over the last month; the price is below its 20-day average.
- News impactLow3 news items and filings in two weeks; 0 rated high impact, 0 medium.
Signals describe activity, not recommendations. Not financial advice.
BioPlus stock overview
BioPlus (바이오플러스, KRX: 099430) is listed on KOSDAQ, in the Biotech & Pharma sector. The company develops, manufactures and sells bio medical devices built on hyaluronic acid (HA), including dermal fillers, anti-adhesion agents, joint tissue repair agents and bladder tissue repair agents. Its shares closed at ₩3,320 on Oct 27, 2026, up 2.00% on the day, giving it a market value of ₩205B.
Key facts
- Market cap
- ₩205B
- Sector
- Biotech & Pharma
- Latest price change
- +2.00%
- As of
- Oct 27, 2026
- Main business
- The company develops, manufactures and sells bio medical devices built on hyaluronic acid (HA), including dermal fillers, anti-adhesion agents, joint tissue repair agents and bladder tissue repair agents.
Quick answers about BioPlus
- What does BioPlus do?
- The company develops, manufactures and sells bio medical devices built on hyaluronic acid (HA), including dermal fillers, anti-adhesion agents, joint tissue repair agents and bladder tissue repair agents. It also offers bio cosmetics, biopharmaceuticals made with recombinant gene technology, and biological ingredients. Its products are sold through partner companies and its own direct sales force in South Korea and overseas, and it is building production and beauty-clinic operations in Hainan, China.
- What is the market cap of BioPlus?
- The market capitalisation of BioPlus was ₩205B at the close on Oct 27, 2026.
- Who are the largest shareholders of BioPlus?
- According to the latest official filings, the largest reported holders are Jung Hyun-gyu (29.82%, as of Oct 8, 2026); Lindeman Asia (4.24%, as of Feb 13, 2025); Korea Securities Finance (3.98%, as of Jan 8, 2026).
- When is the next earnings report from BioPlus?
- Korean companies rarely announce results dates in advance. Based on when BioPlus filed the same report in past years, its next 3q results is expected around Nov 14, 2026.
- Does the National Pension Service own BioPlus?
- Yes. The National Pension Service held 0.42% of BioPlus shares as of Dec 31, 2024.
Company profile
The company develops, manufactures and sells bio medical devices built on hyaluronic acid (HA), including dermal fillers, anti-adhesion agents, joint tissue repair agents and bladder tissue repair agents. It also offers bio cosmetics, biopharmaceuticals made with recombinant gene technology, and biological ingredients. Its products are sold through partner companies and its own direct sales force in South Korea and overseas, and it is building production and beauty-clinic operations in Hainan, China.
Written by AI from the company's latest annual report.
- Korean name
- 바이오플러스
- Sector
- Biotech & Pharma
- Themes
- Biotech (new drugs)
- CEO
- 정현규
- Founded
- May 2003
- Listed
- Sep 2021
- Listed shares
- 61,640,722
- Fiscal year ends
- Month 12
- Website
- bioplus.co.kr
Similar companies
- Samsung Biologics207940 · ₩64T₩1,374,000−5.37%
- Celltrion068270 · ₩44T₩188,600−0.74%
- Alteogen196170 · ₩15T₩218,5000.00%
- Yuhan000100 · ₩5.9T₩80,000−2.08%
- SK biopharmaceuticals326030 · ₩5.9T₩74,900−1.19%
- HLB028300 · ₩5.3T₩39,900+1.66%
- Hanmi Pharm128940 · ₩4.5T₩350,500−0.57%
- SAM Chun Dang Pharm000250 · ₩4.4T₩187,600−0.69%
Recent news
Over 300 domestic and foreign biotech firms gather as 'BioPlus' opens
Predicted impact: Low
Industry expo opening; routine event with no direct financial impact disclosed.
Bioplus launches new filler product with Brazil's Simed
Predicted impact: Low· Actual: −9.4% vs sector, volume 0.8× normal (5 trading days)
New filler product launch with a Brazilian partner; no deal size given.
Recent filings
See all- 5%+ holding reportOct 8, 2026
- Half-year report (Jun 2026)Aug 14, 2026
- Investor relations (IR) eventMay 27, 2026
- Quarterly report (Mar 2026)May 14, 2026
- Adjustment of Conversion PriceApr 30, 2026
Titles in Korean until English translations are added.
Also known as: BioPlus / 바이오플러스 / 099430 / KRX:099430
Source: KRX statistical information